ArticleBMJ open2026
Melatonin to improve sleep in patients undergoing major surgery: protocol for a double-blind, randomised placebo-controlled trial (MELROSE).
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSleep disturbance is common after major surgery and may impair recovery, immune function and postoperative outcomes. Environmental disruptions, pain and routine hospital care often contribute to poor sleep during hospitalisation. Sedative medications such as benzodiazepines are frequently used but may cause adverse effects. Melatonin, a hormone regulating circadian rhythm, has been shown to improve sleep disturbance with a favourable safety profile; however, evidence for its perioperative use remains limited. METHODS AND ANALYSIS: The MELROSE trial is a prospective, double-blind, randomised placebo-controlled trial conducted at John Hunter Hospital. Adults undergoing elective major abdominal or orthopaedic surgery with an expected hospital stay of more than 48 hours are randomised 1:1 to receive melatonin (5 mg sublingual wafer) or placebo. Study medication is administered the night before surgery and nightly postoperatively at 21:00 hours for up to 7 days or until discharge. The primary outcome is the raw Patient-Reported Outcome Measurement Information System (PROMIS) Sleep Disturbance 8a score on postoperative day 3. Secondary outcomes include serum cortisol levels, postoperative complications (Clavien-Dindo classification), length of stay, delirium incidence, 30-day mortality and quality of life with the EuroQuol 5 Dimension 5 levels quality of life scale(EQ-5D-5L). The study aims to recruit 340 participants, with 170 participants per treatment group. The primary analysis will compare treatment groups using an Analysis of Covariance (ANCOVA) model adjusted for baseline PROMIS score and randomisation strata. ETHICS AND DISSEMINATION: This study has been approved by the Hunter New England Human Research Ethics Committee (2019/ETH13791) protocol V11_ 22 January 2026. Study findings will be presented at local and national conferences and in scientific research journals. TRIAL REGISTRATION NUMBER: ACTRN12620000031965.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.